Cantargia: Grant of patent by The European Patent Office (EPO)

Cantargia AB (“Cantargia”) hereby announce that the European Patent Office (EPO) has decided to grant the patent application concerning IL1RAP as a target molecule for antibody therapy and diagnostic methods of leukemia (patent EP2467403). The acknowledgement follow up on the “Intention to Grant” notification, published May 28, 2015.

Receiving this acknowledgement from EPO means that the company obtains a European protection until year 2029 for the company’s method using IL1RAP as target molecule. The protection includes therapy as well as diagnostic methods of leukemia. The patent application is also under review within e.g. USA, Japan and China.

“IL1RAP has a great potential as a target molecule for cancer therapy and the formal grant from the EPO is important and strengthens Cantargia´s patent portfolio as well as the product candidate CAN04”, says Göran Forsberg, CEO at Cantargia.

For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com

About Us

Cantargia AB (publ), reg.no. 556791-6019, is a biotech company which is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at http://www.cantargia.com.

Subscribe

Documents & Links